Cargando…

Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial

BACKGROUND: Due to the critical condition of COVID-19, it is necessary to evaluate the efficacy of administrating convalescent plasma to COVID-19 patients. Therefore, we decided to design a clinical trial to investigate the effect of convalescent plasma of patients recovered from COVID-19 on the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalili, Ebrahim, Khazaei, Salman, Mohammadi, Afshin, Keramat, Fariba, Hashemi, Seyed Hamid, Bashirian, Saeid, Kiani, Toos, Azizi Jalilian, Farid, Ghelichkhani, Samereh, Karami, Manoochehr, Farrokhi, Maryam, Heidarimoghadam, Rashid, Abbasi Garavand, Tahereh, Daneshyar, Ebrahim, Abbasi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Research Institute of Tuberculosis and Lung Disease 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571240/
https://www.ncbi.nlm.nih.gov/pubmed/36258918
_version_ 1784810315401134080
author Jalili, Ebrahim
Khazaei, Salman
Mohammadi, Afshin
Keramat, Fariba
Hashemi, Seyed Hamid
Bashirian, Saeid
Kiani, Toos
Azizi Jalilian, Farid
Ghelichkhani, Samereh
Karami, Manoochehr
Farrokhi, Maryam
Heidarimoghadam, Rashid
Abbasi Garavand, Tahereh
Daneshyar, Ebrahim
Abbasi, Mohammad
author_facet Jalili, Ebrahim
Khazaei, Salman
Mohammadi, Afshin
Keramat, Fariba
Hashemi, Seyed Hamid
Bashirian, Saeid
Kiani, Toos
Azizi Jalilian, Farid
Ghelichkhani, Samereh
Karami, Manoochehr
Farrokhi, Maryam
Heidarimoghadam, Rashid
Abbasi Garavand, Tahereh
Daneshyar, Ebrahim
Abbasi, Mohammad
author_sort Jalili, Ebrahim
collection PubMed
description BACKGROUND: Due to the critical condition of COVID-19, it is necessary to evaluate the efficacy of administrating convalescent plasma to COVID-19 patients. Therefore, we decided to design a clinical trial to investigate the effect of convalescent plasma of patients recovered from COVID-19 on the treatment outcome of COVID-19-infected patients. MATERIALS AND METHODS: In this parallel randomized controlled clinical trial, patients in the intervention group received standard treatment plus convalescent plasma of patients recovered from COVID-19. We allocated 60 patients to each treatment group through balanced block randomization. Then, COVID-19 outcomes, vital signs, and biochemical parameters were compared between the two treatment groups by the independent t test and ANCOVA. RESULTS: The mean age (SD) of the patients in the intervention and standard treatment groups was 52.84 (15.77) and 55.15 (14.34) years, respectively. Although patients in the intervention group reported more hospitalization days (11.45±5.86 vs. 10.42±6.79), death rates (26.67% vs. 18.13%), ICU admission (45 vs. 41.67%), and ARDS (11.67% vs. 3.33%), these differences were not statistically significant (P>0.05). Moreover, the two groups were homogenous in vital signs and biochemical parameters before and after treatment (P>0.05). CONCLUSION: The present study indicated that convalescent plasma therapy has no significant effect on the survival, hospitalization, and ICU admission of COVID-19 patients.
format Online
Article
Text
id pubmed-9571240
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher National Research Institute of Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-95712402022-10-17 Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial Jalili, Ebrahim Khazaei, Salman Mohammadi, Afshin Keramat, Fariba Hashemi, Seyed Hamid Bashirian, Saeid Kiani, Toos Azizi Jalilian, Farid Ghelichkhani, Samereh Karami, Manoochehr Farrokhi, Maryam Heidarimoghadam, Rashid Abbasi Garavand, Tahereh Daneshyar, Ebrahim Abbasi, Mohammad Tanaffos Original Article BACKGROUND: Due to the critical condition of COVID-19, it is necessary to evaluate the efficacy of administrating convalescent plasma to COVID-19 patients. Therefore, we decided to design a clinical trial to investigate the effect of convalescent plasma of patients recovered from COVID-19 on the treatment outcome of COVID-19-infected patients. MATERIALS AND METHODS: In this parallel randomized controlled clinical trial, patients in the intervention group received standard treatment plus convalescent plasma of patients recovered from COVID-19. We allocated 60 patients to each treatment group through balanced block randomization. Then, COVID-19 outcomes, vital signs, and biochemical parameters were compared between the two treatment groups by the independent t test and ANCOVA. RESULTS: The mean age (SD) of the patients in the intervention and standard treatment groups was 52.84 (15.77) and 55.15 (14.34) years, respectively. Although patients in the intervention group reported more hospitalization days (11.45±5.86 vs. 10.42±6.79), death rates (26.67% vs. 18.13%), ICU admission (45 vs. 41.67%), and ARDS (11.67% vs. 3.33%), these differences were not statistically significant (P>0.05). Moreover, the two groups were homogenous in vital signs and biochemical parameters before and after treatment (P>0.05). CONCLUSION: The present study indicated that convalescent plasma therapy has no significant effect on the survival, hospitalization, and ICU admission of COVID-19 patients. National Research Institute of Tuberculosis and Lung Disease 2022-01 /pmc/articles/PMC9571240/ /pubmed/36258918 Text en Copyright© 2022 National Research Institute of Tuberculosis and Lung Disease https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Original Article
Jalili, Ebrahim
Khazaei, Salman
Mohammadi, Afshin
Keramat, Fariba
Hashemi, Seyed Hamid
Bashirian, Saeid
Kiani, Toos
Azizi Jalilian, Farid
Ghelichkhani, Samereh
Karami, Manoochehr
Farrokhi, Maryam
Heidarimoghadam, Rashid
Abbasi Garavand, Tahereh
Daneshyar, Ebrahim
Abbasi, Mohammad
Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial
title Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial
title_full Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial
title_fullStr Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial
title_full_unstemmed Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial
title_short Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial
title_sort effect of convalescent plasma therapy on clinical improvement of covid-19 patients: a randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571240/
https://www.ncbi.nlm.nih.gov/pubmed/36258918
work_keys_str_mv AT jaliliebrahim effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT khazaeisalman effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT mohammadiafshin effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT keramatfariba effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT hashemiseyedhamid effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT bashiriansaeid effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT kianitoos effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT azizijalilianfarid effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT ghelichkhanisamereh effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT karamimanoochehr effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT farrokhimaryam effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT heidarimoghadamrashid effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT abbasigaravandtahereh effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT daneshyarebrahim effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial
AT abbasimohammad effectofconvalescentplasmatherapyonclinicalimprovementofcovid19patientsarandomizedclinicaltrial